SEC Filing Summary: ChromaDex Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation on March 20, 2015, covering an event that occurred on March 17, 2015. The filing addresses a change in the compensatory arrangements for a senior officer. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to a specific executive compensation adjustment.
Material Changes
The Board of Directors approved an increase in the base salary of Troy Rhonemus, the Company's Chief Operating Officer. The salary was raised from $180,000 to $190,000, representing a 5.6% increase effective March 17, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The report is strictly informational regarding the executive salary adjustment.
Investor Verification Points
- Verify the identity of the registrant as ChromaDex Corporation, distinct from the metadata reference to Niagen Bioscience, Inc.
- Confirm the effective date of the COO salary increase is March 17, 2015.
- Note that this filing does not impact reported financial statements or provide operational metrics.